- Home
- ACHL vs ANEB Comparison
ACHL vs ANEB Comparison
Compare ACHL & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- ANEB
- Stock Information
- Founded
- ACHL 2016
- ANEB 2020
- Country
- ACHL United Kingdom
- ANEB United States
- Employees
- ACHL N/A
- ANEB N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- ACHL Health Care
- ANEB Health Care
- Exchange
- ACHL Nasdaq
- ANEB Nasdaq
- Market Cap
- ACHL 43.6M
- ANEB 36.7M
- IPO Year
- ACHL 2021
- ANEB 2021
- Fundamental
- Price
- ACHL $0.95
- ANEB $1.23
- Analyst Decision
- ACHL Buy
- ANEB Buy
- Analyst Count
- ACHL 2
- ANEB 1
- Target Price
- ACHL $4.00
- ANEB $8.00
- AVG Volume (30 Days)
- ACHL 107.8K
- ANEB 8.4K
- Earning Date
- ACHL 11-14-2024
- ANEB 02-11-2025
- Dividend Yield
- ACHL N/A
- ANEB N/A
- EPS Growth
- ACHL N/A
- ANEB N/A
- EPS
- ACHL N/A
- ANEB N/A
- Revenue
- ACHL N/A
- ANEB N/A
- Revenue This Year
- ACHL N/A
- ANEB N/A
- Revenue Next Year
- ACHL N/A
- ANEB N/A
- P/E Ratio
- ACHL N/A
- ANEB N/A
- Revenue Growth
- ACHL N/A
- ANEB N/A
- 52 Week Low
- ACHL $0.63
- ANEB $1.23
- 52 Week High
- ACHL $1.76
- ANEB $3.30
- Technical
- Relative Strength Index (RSI)
- ACHL 29.24
- ANEB 33.17
- Support Level
- ACHL $0.97
- ANEB $1.30
- Resistance Level
- ACHL $1.01
- ANEB $1.50
- Average True Range (ATR)
- ACHL 0.03
- ANEB 0.13
- MACD
- ACHL -0.01
- ANEB -0.01
- Stochastic Oscillator
- ACHL 0.87
- ANEB 0.00
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.